New cGMP Manufacturing Facility

RP Masiello led the design/build program for a new 40,000 sq. ft. complex that supports drug and medical device development, clinical trial supply production, and commercial scale manufacturing of approved therapeutic products.

The building has 10 flexible manufacturing suites that can be configured for various products in the company’s pipeline. There is a full range of support labs for quality assurance, quality control, in-process monitoring and fill-finish for distribution. All of the manufacturing and laboratory areas were built to ISO 7 clean room standards.

The facility meets the rigorous requirements of current Good Manufacturing Practices (cGMP), which is necessary to comply with U.S. FDA and European Medicines Agency (EMA) standards.

EyePoint Pharmaceuticals develops new treatments and drug-delivery systems for serious ophthalmic conditions, including macular degeneration, the leading cause of vision loss among adults.